GlassScriptPhysician profile
Amanda Mosher
NPI 1548997646
$2,110.70
in general payments reported to CMS, 2019-2025
25 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $273 · 2023: $1,070 · 2024: $584 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755 · Education: $57.82 · Consulting Fee: $24.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.15 |
| Education | $57.82 |
| Consulting Fee | $24.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $321.32 | 2022-2024 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $237.52 | 2023-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $174.06 | 2023 | |
| Amgen INC. | $169.10 | 2023-2024 | Repatha, Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $157.50 | 2023-2025 | Dupixent |
| Pfizer INC. | $153.04 | 2022-2024 | |
| Optinose US, INC. | $148.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.44 | 2023-2024 | Glassia, Hyqvia, Takhzyro |
| Atricure, INC. | $105.72 | 2022-2023 | |
| Octapharma USA, INC. | $103.74 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Kaleo, INC. | $58.53 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $45.61 | 2023 | |
| Csl Behring | $36.82 | 2023 | Haegarda |
| Biocryst US Sales Co., LLC | $32.80 | 2023-2024 | Orladeyo |
| Janssen Pharmaceuticals, INC | $31.16 | 2023 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.11 | 2022-2023 | Lifevest |
| Blueprint Medicines Corporation | $26.87 | 2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.46 | 2022 | |
| Adma Biomanufacturing LLC | $24.88 | 2024 | |
| Merck Sharp & Dohme LLC | $24.77 | 2022-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $23.63 | 2023 | Opsumit |
| Genentech USA, INC. | $23.30 | 2024 | Xolair |
| Alnylam Pharmaceuticals INC. | $16.26 | 2022 | |
| Alk-Abello, INC | $16.05 | 2023 | Timothy, Standardized, Standardized Mite D. Farinae, Histamine Positive |
| Cue Health INC. | $13.61 | 2023 | Cue Health Monitoring System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mosher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.